

Amendments to the Specification:

✓
Please amend paragraph 0025 of the specification as follows:

A¹
[0025] Other useful pressure-sensitive adhesives ("PSA") can include acrylic-based pressure-sensitive adhesives and silicone-based pressure-sensitive adhesives as described in U.S. Pat. Nos. 5,474,783, and ~~5,656,386~~ 5,656,286. Suitable commercially available acrylic-based polymers can include adhesives that are commercially available and include the polyacrylate adhesives sold under the trademarks Duro-Tak by National Starch and Chemical Corporation, Bridgewater, N.J., such as Duro-Tak 87-2194, Duro-Tak 87-2196, Duro-Tak 87-1197, 87-4194, 87-2510, 87-2097 and 87-2852. Other suitable acrylic-based adhesives are those sold under the trademarks Gelva-Multipolymer Solution (GMS) (Monsanto; St. Louis, Mo.), such as GMS 737, 788, 1151, 3087 and 7882.

✓
Please amend paragraph 0034 of the specification as follows:

A²
[0034] Illustrative examples of suitable adhesives and flexible, finite delivery systems include those described in U.S. Patent Nos. 5,474,783, and ~~5,656,386~~ 5,656,286 both assigned to Noven Pharmaceuticals, Inc., Miami, Florida (incorporated herein by reference).

✓
Please amend paragraph 0048 of the specification as follows:

A³
[0048] In some instances, the steady decrease may be broadly considered, "substantially zero-order" as that term is used in co-owned Serial No. ~~09/161,351~~ 09/163,351, from which this application claims priority, in that the variability contemplated within the scope of "substantially zero order" of about a 30% to about 40% difference from the mean in the plasma levels of methylphenidate at steady state (6-16 hours after administration) would also include a 30 to 40% decrease from the mean plasma levels of methylphenidate.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

A4
Claim 1. (Currently Amended). A composition for topical application of methylphenidate, comprising methylphenidate and a pharmaceutically acceptable adhesive in a flexible, finite system, wherein said composition comprises no more than about 5 weight % of acid functional monomers and delivers methylphenidate in an amount and rate sufficient to increase the methylphenidate plasma concentration of a subject being treated over a period of about 6-16 hours, followed by a steady decrease in the plasma concentration of methylphenidate.

Claim 2. (Original). The composition according to claim 1, wherein said increase in said methylphenidate plasma concentration is followed by a steady decrease in the plasma concentration of methylphenidate over a period of at least about 8 hours.

Claim 3. (Original). The composition according to claim 1, wherein said increase in said methylphenidate plasma concentration occurs over a period of about 6-12 hours.

Claim 4. (Original). The composition according to claim 1, wherein said increase in said methylphenidate plasma concentration is in the range of 0.06 (ng/mL)/hour to 6.0 (ng/mL)/hour.

Claim 5. (Original). The composition according to claim 1, wherein said increase in said methylphenidate plasma concentration is in the range of 0.4 (ng/mL)/hour to 2.5 (ng/mL)/hour.

Claim 6. (Canceled).

Claim 7. (Original). The composition according to claim 1, wherein said composition is substantially free of ritalinic acid at the time of manufacture.

Claim 8. (Original). The composition according to claim 1, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 24 hours.

Claim 9. (Original). The composition according to claim 1, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 18 hours.

Claim 10. (Original). The composition according to claim 1, wherein the methylphenidate is delivered at a rate of about at least 5 mg per 24 hours.

A4
Cont.
Claim 11. (Currently Amended). A composition for topical application of methylphenidate, comprising methylphenidate and a pharmaceutically acceptable adhesive in a flexible, finite system,

(i) wherein said composition comprises about 10 to 30 wt% methylphenidate, about 30 to 50 wt% acrylic adhesive, and about 30 to 50 wt% silicone adhesive,

(ii) wherein said composition delivers methylphenidate in an amount and rate sufficient to increase the methylphenidate plasma concentration of a subject being treated over a period of about 6-16 hours, followed by a steady decrease in the plasma concentration of methylphenidate, and

(iii) wherein said composition comprises no more than about 5 weight % of acid functional monomers.

Claim 12. (Original). The composition according to claim 11, wherein said increase in said plasma concentration over about 6-16 hours is followed by a steady decrease in the plasma concentration of methylphenidate over a period of at least about 8 hours.

Claim 13. (Original). The composition according to claim 11, wherein said increase in said methylphenidate plasma concentration occurs over a period of about 6-12 hours.

Claim 14. (Original). The composition according to claim 11 wherein said increase in said methylphenidate plasma concentration is in the range of 0.06 (ng/mL)/hour to 6.0 (ng/mL)/hour.

Claim 15. (Canceled).

Claim 16. (Original). The composition according to claim 11, wherein said composition is substantially free of ritalinic acid at the time of manufacture.

Claim 17. (Original). The composition according to claim 11, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 24 hours.

Claim 18. (Original). The composition according to claim 11, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 18 hours.

Claim 19. (Original). The composition according to claim 11, wherein the methylphenidate is delivered at a rate of about at least 5 mg per 24 hours.

Claim 20. (Currently Amended). A method of treating attention deficit disorder and attention deficit/hyperactivity disorder comprising topically administering a composition of methylphenidate and a pharmaceutically acceptable adhesive in a flexible, finite system, wherein said composition comprises no more than about 5 weight % of acid functional monomers and delivers methylphenidate in an amount and rate sufficient to increase the methylphenidate plasma concentration of a subject being treated over a period of about 6-16 hours, followed by a steady decrease in the plasma concentration of methylphenidate.

Claim 21. (Original). The method according to claim 20, wherein the increasing plasma concentration over about 6-16 hours is followed by a steady decrease in the plasma concentration of methylphenidate over a period of at least about 8 hours.

Claim 22. (Original). The method according to claim 20, wherein said increase in said methylphenidate plasma concentration is in the range of 0.06 (ng/mL)/hour to 6.0 (ng/mL)/hour.

Claim 23. (Original). The method according to claim 20, wherein said increase in said methylphenidate plasma concentration is in the range of 0.4 (ng/mL)/hour to 2.5 (ng/mL)/hour.

Claim 24. (Canceled).

Claim 25. (Original). The method according to claim 20, wherein said composition is substantially free of ritalinic acid at the time of manufacture.

A4
cont.
Claim 26. (Original). The method according to claim 20, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 24 hours.

Claim 27. (Original). The method according to claim 20, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 18 hours.

Claim 28. (Original). The method according to claim 20, wherein the methylphenidate is delivered at a rate of about at least 5 mg per 24 hours.

Claim 29. (Currently Amended). A method of treating attention deficit disorder and attention deficit/hyperactivity disorder comprising topically administering a composition of methylphenidate, and a pharmaceutically acceptable adhesive in a flexible, finite system,

(i) wherein said composition comprises about 10 to 30 wt% methylphenidate, about 30 to 50 wt% acrylic adhesive, and about 30 to 50 wt% silicone adhesive,

(ii) wherein said composition delivers methylphenidate in an amount and rate sufficient to increase the methylphenidate plasma concentration of a subject being treated

over a period of about 6-16 hours, followed by a steady decrease in the plasma concentration of methylphenidate, and

(iii) wherein said composition comprises no more than about 5 weight % of acid functional monomers.

Claim 30. (Original). The method according to claim 29, wherein the increasing plasma concentration over about 6-16 hours is followed by a steady decrease in the plasma concentration of methylphenidate over a period of at least about 8 hours.

Claim 31. (Original). The method according to claim 29, wherein said increase in said methylphenidate plasma concentration occurs over a period of about 6-12 hours.

Claim 32. (Original). The method according to claim 29, wherein said increasing plasma concentration is in the range of 0.06 (ng/mL)/hour to 6.0 (ng/mL)/hour.

Claim 33. (Canceled).

Claim 34. (Original). The method according to claim 29, wherein said composition is substantially free of ritalinic acid at the time of manufacture.

Claim 35. (Original). The method according to claim 29, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 24 hours.

Claim 36. (Currently Amended). The method according to claim 29, wherein ~~wherein~~ said composition delivers a therapeutically effective amount over a period of time of about 12 to about 18 hours.

Claim 37. (Original). The method according to claim 29, wherein the methylphenidate is delivered at a rate of about at least 5 mg per 24 hours.

Claim 38. (Original). The method according to claim 20, wherein said increase in said methylphenidate plasma concentration occurs over a period of about 6-12 hours.